iCUREX
Japan · Healthtech · Biotech
Kagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.
Product
iCUREX develops medical devices based on chitosan hydrogel technology. Its Kitosla CX wound dressing is supplied in a syringe so clinicians can place the gel into narrow or irregularly shaped wounds.
The Kagoshima company was founded in October 2023 to commercialise university research in medical materials. It combines product development with manufacturing, quality management and sales.
Kitosla CX received Japanese Class III medical-device approval in May 2026, followed by insurance coverage in July and commercial launch in September. The company is expanding production and developing further products based on its hydrogel technology.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A first close: equity and debt | ¥140M | NCB Venture Capital — LeadGreen Core — ParticipantINDEP — ParticipantJapan Finance Corporation — Participant |